Pfizer scraps insulin deal with India's Biocon
MUMBAI (Reuters) - Pfizer Inc, the world's largest drugmaker, has scrapped a deal to sell insulin products made by Biocon Ltd, leaving India's biggest biotech company without a partner to sell the drugs in key global markets such as the United States. The companies cited "individual priorities" as the reason for the split, which immediately ends a relationship that stood to earn Biocon hundreds of millions of dollars in royalties. ...
Source: news.yahoo.com
No comments:
Post a Comment